However, individuals living with Early Onset FSHD face barriers in accessing clinical trials and competent care as they adapt to an ongoing cycle of muscle and ability loss. On July 1, 2026, the Early Onset community helped the FDA understand the FSHD disease spectrum and the life-long impact of FSHD. Thank you to the courageous youth and caregivers who spoke honestly about FSHD’s relentless progression and the need for a cure accessible to children and the non-ambulatory.